Hot Investor Mandate 2: Japan-based Pharma Seeks Early Stage Assets in Neurology, Diabetes, Immunology & Infectious Diseases

28 Apr

A multinational pharmaceutical company headquartered Japan with a subsidiary based in the USA is actively looking globally for opportunities to in-license cutting-edge, early stage therapeutic assets. Sponsored research may also be considered.

The firm’s external R&D is focused on both neurodegerative and neurodevelopmental diseases including Parkinson’s disease, autism, Rett Syndrome, fragile X, and lysosomal storage diseases. The firm is also interested in diabetes, immunology, and infectious diseases. The firm is seeking platform technology with new MOA such as gene therapy, stem cell therapy, and monoclonal antibody acting on new targets. The firm prefers early stage, pre-POC assets.

The firm is looking for assets that would be strategic a fit with its current portfolio. The firm is willing to negotiate regional rights based each therapeutic field. For example, in immunology and neurology, the firm would prefer both US and Asia rights. In diabetes, infectious diseases, and other areas, the firm can request Asia rights only.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: